Cancer

March 4, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as CCM3/KRIT1, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 4/March/2019, 8.51 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as CCM3/KRIT1, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 4/March/2019, 8.51 pm https://genomediscovery.org/wp-content/uploads/2019/03/Metformin-Navitoclax-and-Dasatinib-MND-function-as-an-anti-tumor.metastasis-agent-by-increasing-the-expression-of-tumor.metastasis-suppressors-including-CCM3.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/Metformin-Navitoclax-and-Dasatinib-MND-function-as-an-anti-tumor.metastasis-agent-by-increasing-the-expression-of-tumor.metastasis-suppressors-including-CCM3.jpg March 4, 2019 March 4, 2019

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in…

March 3, 2019

Combinatorial therapy for EVI-1-Overexpressing Acute Myeloid Leukemia: a therapeutic mix encompassing Simvastatin and Navitoclax/ABT-263 (SAN) decreases the expression of MECOM/EVI-1 and its down target genes, including CKMT-1, alters Arginine-creatine metabolism, inhibits mitochondrial respiration, depletes ATP levels, and promotes regression of EVI-1-overexpressing AML via up regulation of its target gene, 3/March/2017, 11.23 am

Combinatorial therapy for EVI-1-Overexpressing Acute Myeloid Leukemia: a therapeutic mix encompassing Simvastatin and Navitoclax/ABT-263 (SAN) decreases the expression of MECOM/EVI-1 and its down target genes, including CKMT-1, alters Arginine-creatine metabolism, inhibits mitochondrial respiration, depletes ATP levels, and promotes regression of EVI-1-overexpressing AML via up regulation of its target gene, 3/March/2017, 11.23 am https://genomediscovery.org/wp-content/uploads/2019/03/A-therapeutic-mix-encompassing-Simvastatin-brand-name-Zocor-and-Navitoclax.ABT263-SAN-inhibits-the-progression-of-EVI1-overexpressing-human-cancers-by-decreasing-CKMT1-expression-1.jpg2_-1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/A-therapeutic-mix-encompassing-Simvastatin-brand-name-Zocor-and-Navitoclax.ABT263-SAN-inhibits-the-progression-of-EVI1-overexpressing-human-cancers-by-decreasing-CKMT1-expression-1.jpg2_-1.jpg March 3, 2019 March 3, 2019

Introduction: What they say: A study from the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; and Broad Institute of…

March 3, 2019

Combinatorial therapy for attenuating prostate cancer bone metastasis: A pharmaceutical mixture encompassing Simvastatin and Navitoclax (SAN) inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via upregulation of its target gene, 3/March/2019, 8.33 am

Combinatorial therapy for attenuating prostate cancer bone metastasis: A pharmaceutical mixture encompassing Simvastatin and Navitoclax (SAN) inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via upregulation of its target gene, 3/March/2019, 8.33 am https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Simvastatin-and-Navitoclax.ABT263-SAN-functions-as-an-anti-metastasis-agent-in-metastatic-cancers-by-decreasing-MAOA-expression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Simvastatin-and-Navitoclax.ABT263-SAN-functions-as-an-anti-metastasis-agent-in-metastatic-cancers-by-decreasing-MAOA-expression.jpg March 3, 2019 March 3, 2019

Introduction: What they say: A study from the Uro-Oncology Research Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA shows that “MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes…

February 28, 2019

Combinatorial anti-cancer therapy blocking GPC2 pathway and immune receptors enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG) inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 28/February/2019, 8.23 am

Combinatorial anti-cancer therapy blocking GPC2 pathway and immune receptors enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG) inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 28/February/2019, 8.23 am https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxydglucose-MNDDG-inhibits-GPC2Glypican-2-expression-and-enhances-the-efficacy-of-cancer-immuotherapy-in-Neuroblastoma.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxydglucose-MNDDG-inhibits-GPC2Glypican-2-expression-and-enhances-the-efficacy-of-cancer-immuotherapy-in-Neuroblastoma.jpg February 28, 2019 February 28, 2019

National Science day special ********* We wish everyone a very happy national science day. On this special occasion, we are happy to announce that Bio-Med/Pharma/Therapeutic/Clinical ideas posted today (28/February/2019) will be…

February 24, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Canthardin and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 25/February/2019, `1.27 am

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Canthardin and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 25/February/2019, `1.27 am https://genomediscovery.org/wp-content/uploads/2019/02/Cantharidin-functions-as-an-anti-tumor.metastasis-agent-by-increasing-the-expression-of-tumor.metastasis-suppressors-including-TPM1-TIMP3-p53.21-TA-p73.p63-and-INK4a.ARF_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/Cantharidin-functions-as-an-anti-tumor.metastasis-agent-by-increasing-the-expression-of-tumor.metastasis-suppressors-including-TPM1-TIMP3-p53.21-TA-p73.p63-and-INK4a.ARF_.jpg February 24, 2019 February 24, 2019

February 24, 2019

The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: A therapeutic mix encompassing Metformin, Navitoclax, dasatinib, 2-deoxy-d-glucose (2DG) (MNDDG) inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 25/February/2019, 1.17 am

The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: A therapeutic mix encompassing Metformin, Navitoclax, dasatinib, 2-deoxy-d-glucose (2DG) (MNDDG) inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 25/February/2019, 1.17 am https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxydglucose-MNDDG-inhibits-PTPN2-and-increases-the-efficacy-of-cancer-immunotherapy2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxydglucose-MNDDG-inhibits-PTPN2-and-increases-the-efficacy-of-cancer-immunotherapy2.jpg February 24, 2019 February 24, 2019

Introduction: What they say: A recent study from Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts…

Popular Post